Pharmacokinetics and Pharmacodynamics of Edoxaban, a Non-Vitamin K Antagonist Oral Anticoagulant that Inhibits Clotting Factor Xa

Clinical Pharmacokinetics

Volumn 55, Issue 6, 2016, Pages 641-655

  Parasrampuria, Dolly A ^a   Truitt, Kenneth E ^a  

^a DAIICHI SANKYO INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYANOCOBALAMIN; EDOXABAN; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; CYTOCHROME P450 3A; PROTEIN BINDING; PYRIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

AGE; ARTICLE; BILE SECRETION; CARDIOVASCULAR DISEASE; DRUG ABSORPTION; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXPOSURE; DRUG METABOLISM; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TRANSPORT; ELIMINATION HALF-LIFE; HUMAN; KIDNEY FUNCTION; LIVER FUNCTION; MAXIMUM PLASMA CONCENTRATION; PARTIAL THROMBOPLASTIN TIME; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTHROMBIN TIME; RACE; RENAL CLEARANCE; SEX; UPPER GASTROINTESTINAL TRACT; VOLUME OF DISTRIBUTION AT STEADY-STATE; AREA UNDER THE CURVE; BLOOD CLOTTING; DOSE RESPONSE; DRUG INTERACTION; HALF LIFE TIME; KIDNEY FAILURE; LIVER FAILURE; METABOLIC CLEARANCE RATE; METABOLISM;

ANTICOAGULANTS; AREA UNDER CURVE; BLOOD COAGULATION; CYTOCHROME P-450 CYP3A; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FACTOR XA INHIBITORS; HALF-LIFE; HUMANS; LIVER FAILURE; METABOLIC CLEARANCE RATE; PROTEIN BINDING; PYRIDINES; RENAL INSUFFICIENCY; THIAZOLES;

EID: 84948995401     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-015-0342-7     Document Type: Article

References (57)

1. Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):e419S–94S.
2. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, et al. 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33(21):2719–47.
3. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation. 2014;130(23):2071–104.
4. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008;133(6 Suppl):160S–98S.
5. Wells PS, Holbrook AM, Crowther NR, Hirsh J. Interactions of warfarin with drugs and food. Ann Intern Med. 1994;121(9):676–83.
6. Furugohri T, Isobe K, Honda Y, Kamisato-Matsumoto C, Sugiyama N, Nagahara T, et al. DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles. J Thromb Haemost. 2008;6(9):1542–9.
7. Matsushima N, Lee F, Sato T, Weiss D, Mendell J. Bioavailability and safety of the factor Xa inhibitor edoxaban and the effects of quinidine in healthy subjects. Clin Pharm Drug Dev. 2013;2:358–66.
8. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093–104.
9. The Hokusai VTE Investigators, Buller HR, Decousus H, Grosso MA, Mercuri M, Middeldorp S, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013;369(15):1406–15.
10. ® (edoxaban tosilate hydrate tablets): full prescribing information. Tokyo: Daiichi Sankyo Company, Ltd.; 2014.
11. Savaysa™ (edoxaban) tablets for oral use: full prescribing information. Parsippany: Daiichi Sankyo Inc.; 2015.
12. ® (edoxaban) approved for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation and for the treatment and prevention of recurrent venous thromboembolism in Switzerland [press release]. April 15, 2015. Available at www.daiichisankyo.com/media_investors/media_relations/press_releases/detail/006269.html.
13. ® (edoxaban): package leaflet. Munich: Daiichi Sankyo Europe GmbH; 2015.
14. Fuji T, Fujita S, Kawai Y, Nakamura M, Kimura T, Kiuchi Y, et al. Safety and efficacy of edoxaban in patients undergoing hip fracture surgery. Thromb Res. 2014;133(6):1016–22.
15. Fuji T, Wang CJ, Fujita S, Kawai Y, Kimura T, Tachibana S. Safety and efficacy of edoxaban, an oral factor Xa inhibitor, for thromboprophylaxis after total hip arthroplasty in Japan and Taiwan. J Arthroplasty. 2014;29(12):2439–46.
16. Fuji T, Fujita S, Kawai Y, Nakamura M, Kimura T, Fukuzawa M, et al. Efficacy and safety of edoxaban versus enoxaparin for the prevention of venous thromboembolism following total hip arthroplasty: STARS J-V. Thromb J. 2015;13:27.
17. Daiichi Sankyo, Inc. Savaysa (edoxaban tosylate): FDA Cardiovascular and Renal Drugs Advisory Committee briefing document. NDA 206316. Meeting date: October 30, 2014. Available at: http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/ucm420703.htm. Accessed 5 Nov 2015.
18. Mikkaichi T, Yoshigae Y, Masumoto H, Imaoka T, Rozehnal V, Fischer T, et al. Edoxaban transport via P-glycoprotein is a key factor for the drug’s disposition. Drug Metab Dispos. 2014;42(4):520–8.
19. Amidon GL, Lennernas H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12(3):413–20.
20. Ogata K, Mendell-Harary J, Tachibana M, Masumoto H, Oguma T, Kojima M, et al. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol. 2010;50(7):743–53.
21. Bathala MS, Masumoto H, Oguma T, He L, Lowrie C, Mendell J. Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans. Drug Metab Dispos. 2012;40(12):2250–5.
22. Parasrampuria D, Weilert J, Maa J, He L, Shi M, Brown K. Pharmacokinetics (PK) of edoxaban, a novel oral anticoagulant (NOAC), when dosed alone or following switching from dabigatran or rivaroxaban. Clin Pharmacol Ther. 2014;95(Suppl 1):S83.
23. Parasrampuria DA, Kanamaru T, Connor A, Wilding I, Ogata K, Shimoto Y, et al. Evaluation of regional gastrointestinal absorption of edoxaban using the enterion capsule. J Clin Pharmacol. 2015 [Epub ahead of print].
24. Mendell J, Tachibana M, Shi M, Kunitada S. Effects of food on the pharmacokinetics of edoxaban, an oral direct factor Xa inhibitor, in healthy volunteers. J Clin Pharmacol. 2011;51(5):687–94.
25. Yin OQ, Miller R. Population pharmacokinetics and dose–exposure proportionality of edoxaban in healthy volunteers. Clin Drug Investig. 2014;34(10):743–52.
26. Masumoto H, Yoshigae Y, Watanabe K, Takakusa H, Okazaki O, Izumi T. In vitro metabolism of edoxaban and the enzymes involved in the oxidative metabolism of edoxaban. AAPS J. 2010;12 (Suppl 2):Abstract W4308.
27. Ogura Y, Masumoto H, Yoshigae Y, Kosaka T, Shinagawa A. Identification of human hydrolase involved in the metabolism of edoxaban to a human major metabolite. AAPS J. 2010;12:Abstract W4298.
28. Jonsson S, Simonsson US, Miller R, Karlsson MO. Population pharmacokinetics of edoxaban and its main metabolite in a dedicated renal impairment study. J Clin Pharmacol. 2015 May 12 [Epub ahead of print].
29. Vandell A, Lee J, Shi M, Rubets I, Brown K, Walker JR. Lack of an affect of the ABCB1 C3435T (RS104564) polymorphism on the pharmacokinetics of edoxaban, a novel factor Xa inhibitor. Clin Pharmacol Therap. 2014;95(Suppl 1):S74.
30. Mendell J, Shi M. Safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) profiles of edoxaban in healthy post-menopausal or surgically sterile females, and healthy elderly males. Eur Heart J. 2011;32(Suppl 1):461.
31. Ridout G, de la Motte S, Niemczyk S, Sramek P, Johnson L, Jin J, et al. effect of renal function on edoxaban pharmacokinetics and on population PK model. J Clin Pharmacol. 2009;49:1091–130 (Abstract 144).
32. Mendell J, Johnson L, Chen S. An open-label, phase 1 study to evaluate the effects of hepatic impairment on edoxaban pharmacokinetics and pharmacodynamics. J Clin Pharmacol. 2015 May 22 [Epub ahead of print].
33. Yin OQ, Tetsuya K, Miller R. Edoxaban population pharmacokinetics and exposure-response analysis in patients with non-valvular atrial fibrillation. Eur J Clin Pharmacol. 2014;70(11):1339–51.
34. Zahir H, Mendell J, Jin J, He L, Parasrampuria DA. The effect of ketoconazole on the pharmacokinetics and pharmacodynamics of edoxaban in healthy adults. Clin Pharm Drug Dev. 2014;(Suppl 1):1–59.
35. FDA Center for Drug Evaluation Research. FDA draft guidance for industry: drug interaction studies—study design, data analysis, implications for dosing, and labeling recommendations. 2012. Available at: http://www.fda.gov/downloads/Drugs/Guidances/ucm292362.pdf. Accessed 17 Apr 2015.
36. Flockhart DA. Drug interactions: cytochrome P450 drug interaction table. Indiana University School of Medicine. 2009. Available at: https://static.medicine.iupui.edu/divisions/clinpharm/content/p450_Table_Oct_11_2009.pdf. Accessed 20 Apr 2015.
37. Mendell J, Zahir H, Matsushima N, Noveck R, Lee F, Chen S, et al. Drug–drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor. Am J Cardiovasc Drugs. 2013;13(5):331–42.
38. Mendell J, Zhang G, He L, Parasrampuria DA. The effects of erythromycin on the pharmacokinetics and pharmacodynamics of edoxaban. Clin Pharmacol Drug Dev. 2014;3(Suppl 1):1–59.
39. Matsushima N, Zahir H, Mendell J, Chen S, He L, Parasrampuria DA. Coadministration of cyclosporine increased edoxaban exposure in healthy adults. Clin Pharmacol Drug Dev. 2014;3(Suppl 1):1–59.
40. ® (amiodarone HCl) tablets: full prescribing information. Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.; Philadelphia. 2014. Available at: http://labeling.pfizer.com/showlabeling.aspx?id=93. Accessed 28 Mar 2015.
41. Robinson K, Johnston A, Walker S, Mulrow JP, McKenna WJ, Holt DW. The digoxin–amiodarone interaction. Cardiovasc Drugs Ther. 1989;3(1):25–8.
42. Mendell J, Chen S, He L, Desai M, Parasramupria DA. The effect of rifampin on the pharmacokinetics of edoxaban in healthy adults. Clin Drug Investig. 2015;35(7):447–53.
43. Mendell J, Lee F, Chen S, Worland V, Shi M, Samama MM. The effects of the antiplatelet agents, aspirin and naproxen, on pharmacokinetics and pharmacodynamics of the anticoagulant edoxaban, a direct factor Xa inhibitor. J Cardiovasc Pharmacol. 2013;62(2):212–21.
44. Zahir H, Matsushima N, Halim AB, He L, Zhang G, Lee F, et al. Edoxaban administration following enoxaparin: a pharmacodynamic, pharmacokinetic, and tolerability assessment in human subjects. Thromb Haemost. 2012;108(1):166–75.
45. Mendell J, Lasseter K, Shi M. Effect of esomeprazole on edoxaban pharmacokinetics and pharmacodynamics when administered orally as tablet and as solution. Eur J. 2011;13 (Suppl 3):Abstract P1052.
46. Eriksson BI, Quinlan DJ, Eikelboom JW. Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism. Annu Rev Med. 2011;62:41–57.
47. Song S, Kang D, Halim AB, Miller R. Population pharmacokinetic–pharmacodynamic modeling analysis of intrinsic FXa and bleeding from edoxaban treatment. J Clin Pharmacol. 2014;54(8):910–6.
48. Weitz JI, Connolly SJ, Patel I, Salazar D, Rohatagi S, Mendell J, et al. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost. 2010;104(3):633–41.
49. Salazar DE, Mendell J, Kastrissios H, Green M, Carrothers TJ, Song S, et al. Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation. Thromb Haemost. 2012;107(5):925–36.
50. Zafar MU, Vorchheimer DA, Gaztanaga J, Velez M, Yadegar D, Moreno PR, et al. Antithrombotic effects of factor Xa inhibition with DU-176b: phase-I study of an oral, direct factor Xa inhibitor using an ex-vivo flow chamber. Thromb Haemost. 2007;98(4):883–8.
51. Wolzt M, Samama MM, Kapiotis S, Ogata K, Mendell J, Kunitada S. Effect of edoxaban on markers of coagulation in venous and shed blood compared with fondaparinux. Thromb Haemost. 2011;105(6):1080–90.
52. Samama MM, Kunitada S, Oursin A, Depasse F, Heptinstall S. Comparison of a direct factor Xa inhibitor, edoxaban, with dalteparin and ximelagatran: a randomised controlled trial in healthy elderly adults. Thromb Res. 2010;126(4):e286–93.
53. Parasrampuria DA, Weilert D, Maa J-F, Dishy V, Kochan J, Shi M, et al. Switching from dabigatran or rivaroxaban to edoxaban: a biomarker assessment in healthy subjects. Thromb Haemost. 2014;12(Suppl 1): 1–106 (Abstract COA41).
54. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonised tripartite guideline: the clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs E14. Geneva. 2005. Available at: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E14/E14_Guideline.pdf. Accessed 5 Nov 2015.
55. Mendell J, Basavapathruni R, Swearingen D, Draves A, Zhang G, Morganroth J. A thorough electrocardiogram study of edoxaban, a novel factor Xa inhibitor. J Clin Pharmacol. 2011;51(8):1241–6.
56. Mendell J, Noveck RJ, Shi M. A randomized trial of the safety, pharmacokinetics and pharmacodynamics of edoxaban, an oral factor Xa inhibitor, following a switch from warfarin. Br J Clin Pharmacol. 2013;75(4):966–78.
57. Ruff CT, Giugliano RP, Braunwald E, Mercuri M, Curt V, Betcher J, et al. Transition of patients from blinded study drug to open-label anticoagulation: the ENGAGE AF–TIMI 48 trial. J Am Coll Cardiol. 2014;64(6):576–84.